title: Management of calcium and bone abnormalities in hemodialysis patients.
abstract: In chronic renal failure, hyperphosphatemia, hypocalcemia, hyperparathyroidism, reduced activation of vitamin D, decreased level of calcium-sensing receptor, osteitis fibrosa, and osteomalacia are features related to calcium abnormalities. Hyperparathyroidism is a risk factor for survival of hemodialysis patients as well as hypoparathyroidism, which is another feature in hemodialysis patients. Treatment of these abnormalities includes control of parathyroid hormone (PTH) secretion, counteracting hyperphosphatemia, correction of hypocalcemia, and others. Various kinds of vitamin D analogs have been introduced recently in addition to calcitriol and alfacalcidol, which have a rather long history (eg, maxacalcitol and falecalcitriol). Sevelamer is a newly developed phosphate binder to treat soft-tissue calcification.
authors.affiliation: Osaka City University, Osaka, Japan.
authors.forename: Hirotoshi
authors.initials: H
authors.lastname: Morii
authors.forename: Tayuki
authors.initials: T
authors.lastname: Inoue
authors.forename: Takaaki
authors.initials: T
authors.lastname: Nishijima
authors.forename: Takashi
authors.initials: T
authors.lastname: Tomokuni
authors.forename: Takatoshi
authors.initials: T
authors.lastname: Ishikawa
authors.forename: Kenji
authors.initials: K
authors.lastname: Moriya
authors.forename: Nobuaki
authors.initials: N
authors.lastname: Kawai
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Araki
authors.forename: Misa
authors.initials: M
authors.lastname: Horio
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Shigeoka
authors.forename: Koji
authors.initials: K
authors.lastname: Tani
authors.forename: Tadashi
authors.initials: T
authors.lastname: Yamaguchi
authors.forename: Noboru
authors.initials: N
authors.lastname: Kubodera
mesh_terms: D001847:Bone Diseases / Q000188:drug therapy* / Q000209:etiology*; D002128:Calcium Metabolism Disorders / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D006435:Renal Dialysis / Q000009:adverse effects*; D014807:Vitamin D / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D014807:Vitamin D